Latest News and Press Releases

KING OF PRUSSIA, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders, today...

KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it...

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in patients with advanced solid tumors ST-01156 has received U.S. FDA Orphan...

KING OF PRUSSIA, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically...

KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically...

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD) gathered on September 6, 2025, at the NYU Grossman School of Medicine,...

Nomination recognizes SEED’s pioneering work inmolecular glue development in targeted protein degradationto address high unmet medical needs Follows recent FDA IND clearance for SEED’slead asset...

 • First Patient Dosing Expected in Q1 2026 • Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers KING OF PRUSSIA, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics,...

KING OF PRUSSIA, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of innovative...

Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected mid-2025Dual PROTAC strategy overcomes hook effect and enhances KRAS G12D...